Quetiapine (Seroquel XR)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Schizophrenia
NCT01810380 · H. Lundbeck A/S
2013-03 – 2014-12 · Schizophrenia
What this study did
NCT01672554 · Corporation de Recherche en Neuropsycho Pharmacologie de Quebec
2008-12 – 2013-10 · Schizophrenia, Anxiety
What this study did
NCT02142556 · Tri-Service General Hospital (TSGH)
2008-11 – 2012-03 · Schizophrenia
What this study did
NCT01071135 · Hannover Medical School
2009-09 – 2010-08 · Schizophrenia
What this study did
NCT00852631 · AstraZeneca
2009-02 – 2010-05 · Schizophrenia
What this study did
NCT00334126 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-04 – 2007-09 · Schizophrenia
What this study did
NCT00161018 · University of Maryland, Baltimore
2003-11 – 2004-11 · Schizophrenia
What this study did
Other / comorbidity
NCT00434876 · Subhajit Chakravorty
2007-08 – 2009-12 · Alcoholism, Sleep Initiation and Maintenance Disorders
What this study did
NCT00600756 · AstraZeneca
2008-01 – 2009-10 · Schizophrenic Disorders
What this study did
Phase 2 (2)
Major Depressive Disorder
NCT01189318 · Ewha Womans University
2012-03 – 2014-02 · Major Depressive Disorder
What this study did
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02087631 · University of Calgary
2014-12 – 2019-07 · Multiple Sclerosis
What this study did
Phase 1 (3)
Schizophrenia
NCT02901587 · H. Lundbeck A/S
2016-09 – 2018-04-18 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00919607 · AstraZeneca
2009-06 – 2010-03 · Schizophrenia
What this study did
Other / comorbidity
NCT00832221 · AstraZeneca
2009-01 – 2009-09 · Depression
What this study did
Phase 4 (16)
Major Depressive Disorder
NCT01357967 · Inje University
2011-05 – 2013-04 · Major Depressive Disorder
What this study did
NCT00982345 · Indiana University
2009-03 – 2012-03 · Major Depression
What this study did
Schizophrenia
NCT01213836 · AstraZeneca
2010-11 – 2011-08 · Schizophrenia
What this study did
NCT00986167 · Bayside Health
2009-10 – 2010-10 · Schizophrenia, Psychosis
What this study did
NCT01047215 · Taichung Veterans General Hospital
2009-08 – 2010-06 · Schizophrenia, Bipolar
What this study did
NCT00954122 · AstraZeneca
2009-09 – 2010-04 · Schizophrenia
What this study did
NCT00779506 · AstraZeneca
2008-11 – 2009-07 · Schizophrenia
What this study did
NCT00681629 · AstraZeneca
2008-07 – 2008-11 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
What this study did
NCT00498004 · Inje University
2007-08 – 2008-09 · Schizophrenia
What this study did
NCT00182442 · Hamilton Health Sciences Corporation
2003-10 – 2006-03 · Schizophrenia
What this study did
NCT00061802 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-06 – 2004-02 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT00983320 · Université de Sherbrooke
2008-04 – 2011-10 · Fibromyalgia
What this study did
NCT00926393 · AstraZeneca
2009-06 – 2009-08 · Bipolar Depression
What this study did
NCT00352469 · Creighton University
2006-02 – 2008-11 · Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, Panic Disorder, Obsessive-Compulsive Disorder
What this study did
Early phase / not applicable (2)
Major Depressive Disorder
NCT01971203 · Icahn School of Medicine at Mount Sinai
2009-09 – 2013-06 · Major Depressive Disorder, Generalized Anxiety Disorder
What this study did
Other / comorbidity
NCT01066143 · Mclean Hospital
2010-02 – 2013-02 · Generalized Anxiety Disorder, Seroquel XR
What this study did
Used as active comparator (11)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Bipolar Disorder
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
Major Depressive Disorder
NCT01727726 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2012-12 – 2016-11-10 · Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
What this study did
Schizophrenia
NCT04115319 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2019-11-21 – 2022-12-30 · Schizophrenia
What this study did
NCT03465787 · Bukwang Pharmaceutical
2018-04-09 – 2022-10-26 · Schizophrenia
What this study did
NCT00789698 · Sumitomo Pharma America, Inc.
2008-12 – 2011-07 · Chronic Schizophrenia
What this study did
NCT00790192 · Sumitomo Pharma America, Inc.
2008-10 – 2010-07 · Schizophrenia
What this study did
Phase 1 (2)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
Phase 4 (3)
Schizophrenia
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT00508157 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11-01 – 2009-03-01 · Metabolic Syndrome, Schizophrenia
What this study did
NCT00654576 · Central South University
2005-02 – 2007-12 · Schizophrenia
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Schizophrenia
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
Phase 2 (2)
Schizophrenia
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
Other / comorbidity
NCT00893841 · Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
2009-02 – 2013-01 · Bipolar Depression
What this study did
Phase 4 (2)
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
NCT00325689 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-10 · Schizophrenia, Schizoaffective Disorder
What this study did
Early phase / not applicable (1)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Quetiapine (Seroquel XR): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Quetiapine (Seroquel XR) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2032 (1)
February 2032 (1)
Phase 2SchizophreniaNot yet recruiting
Est. primary completion 2032-02-01 · NCT07152184 · CT.gov ↗
What to watch

See the full readout calendar ↗